See the latest Coronavirus Information including testing sites, visitation restrictions, appointments and scheduling, and more.
Adults (18-65), Geriatrics (65+)
English and French
Adults (18-65), Geriatrics (65+)
English and French
Recognized by America's Top Doctors, 2013 - 2018
Recognized by Best Doctors in America, 2009 - 2016
Recognized in Philadelphia magazine's annual Top Docs issues, 2018 - 2020
Perelman Center for Advanced Medicine
West Pavilion, 4th Floor
3400 Civic Center Boulevard
Philadelphia, PA 19104
A facility of the Hospital of the University of Pennsylvania
Penn Medicine Valley Forge
1001 Chesterbrook Boulevard
Berwyn, PA 19312
The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.
Leukemia, myelodysplastic syndrome, myeloproliferative disordersMDS, AML, CML, ALL
McMahon CM; Ferng T; Canaani J; Wang ES; Morrissette JJD; Eastburn DJ; Pellegrino M; Durruthy-Durruthy R; Watt CD; Asthana S; Lasater EA; DeFilippis R; Peretz CAC; McGary LHF; Deihimi S; Logan AC; Luger SM; Shah NP; Carroll M; Smith CC; Perl AE.: Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia Cancer Discovery : 2020.
Foss, FM, Wang, XV, Luger, SM, Jegede, O, Miller, KB, Stadtmauer, EA, Whiteside, TL, Avigan, DE, Gascoyne, RD, Arber, D, Wagner, H, Strair, RK, Hogan, WJ, Sprague, KA, Lazarus, HM, Litzow, MR, Tallman, MS, Horning, SJ: Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902 Transfusion 60 (8): 1867-1872,2020.
Zeidan, AM, Boddu, PC, Patnaik, MM, Bewersdorf, JP, Stahl, M, Rampal, RK, Shallis, RM, Steensma, DP, Savona, MR, Sekeres, MA, Roboz, GJ, DeAngelo, DJ, Schuh, AC, Padron, E, Zeidner, JF, Walter, RB, Onida, F, Fathi, AT, DeZern, A, Hobbs, G, Stein, EM, Vyas, P, Wei, AH, Bowen, DT, Montesinos, P, Griffiths, EA, Verma, AK, Keyzner, A, Bar-Natan, M, Navada, SC, Kremyanskaya, M, Goldberg, AD, Al-Kali, A, Heaney, ML, Nazha, A, Salman, H, Luger, S, Pratz, KW, Konig, H, Komrokji, R, Deininger, M, Cirici, BX, Bhatt, VR, Silverman, LR, Erba, HP, Fenaux, P, Platzbecker, U, Santini, V, Wang, ES, Tallman, MS, Stone, RM, Mascarenhas, J: Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts Lancet Haematol. 7 (8): E601-E612,2020.
Kim GYG; Burns J; Freyer CW; Hamilton KW; Frey NV; Gill SI; Hexner EO; Luger SM; Mangan JK; Martin ME; McCurdy SR; Perl AE; Porter DL; Schuster MG; Stadtmauer EA; Loren AW.: Risk of invasive fungal infections in patients with high-risk MDS and AML receiving hypomethylating agents. Am J Hematol 95 : 792-798,2020.
Kim, GY, Burns, J, Freyer, CW, Hamilton, KW, Frey, NV, Gill, SI, Hexner, EO, Luger, SM, Mangan, JK, Martin, ME, McCurdy, SR, Perl, AE, Porter, DL, Schuster, MG, Stadtmauer, EA, Loren, AW: Risk of invasive fungal infections in patients with high-risk MDS and AML receiving hypomethylating agents Am J Hematol 95 (7): 792-798,2020.
Freyer, CW, Carulli, A, Ganetsky, A, Hughes, ME, Krause, TM, Timlin, C, Frey, NV, Gill, SI, Hexner, EO, Loren, AW, Mangan, JK, Martin, ME, McCurdy, SR, Perl, AE, Pratz, K, Porter, DL, Luger, SM: Venous thromboembolism following pegaspargase in adults receiving antithrombin supplementation Leukemia & Lymphoma 61 (9): 2200-2207,2020.
Pagel, JM, Othus, M, Garcia-Manero, G, Fang, M, Radich, JP, Rizzieri, DA, Marcucci, G, Strickland, SA, Litzow, MR, Savoie, ML, Spellman, SR, Confer, DL, Chell, JW, Brown, M, Medeiros, BC, Sekeres, MA, Lin, TL, Uy, GL, Powell, BL, Bayer, RL, Larson, RA, Stone, RM, Claxton, D, Essell, J, Luger, SM, Mohan, SR, Moseley, A, Erba, HP, Appelbaum, FR: Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia JCO Oncolocy Practice 16 (6): 331-+,2020.
Pine, AB, Chokr, N, Stahl, M, Steensma, DP, Sekeres, MA, Litzow, MR, Luger, SM, Stone, RM, Greenberg, PL, Bejar, R, Bewersdorf, JP, Gore, SD, Zeidan, AM: Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey Leukemia & Lymphoma 61 (6): 1455-1464,2020.
Shallis, RM, Stahl, M, Wei, W, Montesinos, P, Lengline, E, Neukirchen, J, Bhatt, VR, Sekeres, MA, Fathi, AT, Konig, H, Luger, S, Khan, I, Roboz, GJ, Cluzeau, T, Martinez-Cuadron, D, Raffoux, E, Germing, U, Umakanthan, JM, Mukhereje, S, Brunner, AM, Miller, A, McMahon, CM, Ritchie, EK, Rodriguez-Veiga, R, Itzykson, R, Boluda, B, Rabian, F, Tormo, M, Cruz, EA, Rabinovich, E, Yoo, B, Cano, I, Podoltsev, NA, Bewersdorf, JP, Gore, S, Zeidan, AM: Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy Leukemia & Lymphoma 61 (5): 1220-1225,2020.
Frey NV; Shaw PA; Hexner EO; Pequignot E; Gill S; Luger SM; Mangan JK; Loren AW; Perl AE; Maude SL; Grupp SA; Shah NN; Gilmore J; Lacey SF; Melenhorst JJ; Levine BL; June CH; Porter DL.: Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia J Clin Oncol 38 : 2020.
Division of Hematology OncologyPerelman Center for Advanced Medicine12th Floor, South PavilionOffice #12-15734th and Civic Center Blvd
Patient appointments: 800-789-7366
Proton therapy is a non–invasive, incredibly precise cancer treatment that uses a beam of protons moving at very high speeds to destroy cancer cells.
Our experienced cancer nurses and referral staff are here to help. Call 800-789-7366 (PENN) or complete an online request.
Learn more about the benefits of translational research at Penn Medicine.